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ABSTRACT

Provided are his-quaternary ammonium compounds which
are modulators of nicotinic acetylcholine receptors. Also
provided are methods of using the compounds for modulating the function of a nicotinic acetylcholine receptor, and for
the prevention and/or treatment of central nervous system
disorders, substance use and/or abuse, and or gastrointestinal
tract disorders.
16 Claims, 1 Drawing Sheet
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HIS-QUATERNARY AMMONIUM SALTS AND
METHODS FOR MODULATING NEURONAL
NICOTINIC ACETYLCHOLINE RECEPTORS

evaluated in clinical trials for cognitive enhancement and
neuroprotective effects, potentially beneficial for disease
states such as Alzheimer's and Parkinson's disease.

FIELD OF THE INVENTION

SUMMARY OF INVENTION

The invention relates to his-quaternary ammonium salts
and their use in modulating nicotinic acetylcholine receptors.

In one embodiment, compounds corresponding to the
following structure are provided.
10

BACKGROUND OF THE INVENTION
S(-)-nicotine (NIC) activates presynaptic and postsynaptic neuronal nicotinic receptors that evoke the release of
neurotransmitters from presynaptic terminals and that
modulate the depolarization state of the postsynaptic neuronal membrane, respectively. Thus, nicotine produces its
effect by binding to a family of ligand-gated ion channels,
stimulated by acetylcholine (ACh) or nicotine which causes
the ion channel to open and cations to flux with a resulting
rapid (millisecond) depolarization of the target cell.
Neuronal nicotinic receptors are composed of two types
of subunits, a and ~' and assemble as heteromeric receptors
with the general stoichiometry of 2a and 3~ or as homomeric receptors with Sa subunits. Nine subtypes of the a
subunit (a2 to alO) and three subtypes of the~ unit (~2 to
(~4) are found in the central nervous system. The most
common nicotinic receptor subtype in the brain is composed
of two a4 and three ~2 subunits, i.e., a4~2. These subunits
display different, but overlapping, patterns of expression in
the brain. Examples of heteromeric receptor subtypes
include a4~2, a3~2, a3~4, a6~2, a4a5~2, a6a5~2,
a4a6~2, a4~2~4, a3~2~4, and others. The predominant
homomeric subtype includes a7, but other combinations
have also been proposed.
For the most part, the actual subunit compositions and
stoichiometries of nicotinic receptors in the brain remain to
be elucidated. Thus, neuronal nicotinic receptor subtype
diversity originates from differences in the amino acid
sequence at the subunit level and from the multiple combinations of assemblies of subunits into functional receptor
proteins, which affords a wide diversity of pharmacological
specificity.
In spite of the extensive diversity in neuronal nicotinic
receptor messenger RNA expression, only a limited number
of tools are available to study the pharmacology of native
receptors. Radioligands are used in many studies. [3 H]NIC
appears to label the same sites in the brain as [3 H]ACh. It has
been estimated that over 90% of [3 H]NIC binding in the
brain is due to association with the heteromeric receptor that
is composed of a4 and ~2 subunits. Also abundant in the
central nervous system are the homomeric receptors labeled
by [3 H]methyllycaconitine (MLA), which has high affinity
for the a7 nicotinic receptor subtype. Nicotinic receptor
subtypes can be studied using functional assays, such as
NIC-evoked neurotransmitter release (e.g., [3 H]dopamine
(DA) release, [3 H]norepinephrine (NE) release, [3 H]serotonin (5-HT) release, [3 H]gamma-aminobutyric acid
(GABA) release and [3 H]glutamate release) from superfused rat brain slices. Nicotinic receptors are located in the
cell body and terminal areas of these neurotransmitter systems. NIC facilitates neurotransmitter release from nerve
terminals.
The structural and functional diversity of central nervous
system nicotinic receptors has stimulated a great deal of
interest in developing novel, subtype-selective agonists and/
or antagonists. Some of these agonists are currently being
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X
and X
are each independently an organic or
inorganic anion.
R is chosen from the group consisting of alkyl, substituted
alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, substituted
alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl,
arylalkyl, substituted arylalkyl, arylalkenyl, substituted arylalkenyl, arylalkynyl, substituted arylalkynyl, heterocyclic,
substituted heterocyclic, alkoxy, alkylamine and thioalkyl.
R 1 and R 2 are each independently five or six membered
rings as shown in formulas (IIA) and (liB), wherein each
ring of R 1 and R 2 has one, two or three nitrogen atoms, each
ring of R 1 and R 2 has one quaternized nitrogen, and the ring
atoms from R 1 and R 2 which are attached toR cannot both
be nitrogen atoms.
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A 1 is carbon or nitrogen, provided that when A 1 joins a
ring atom with an unsaturated bond or is a nitrogen, R 3 is
absent, and when A 1 joins a ring atom with an unsaturated
bond and is a nitrogen, both R 3 and R4 are absent.
A 2 is carbon or nitrogen, provided that when A 2 joins a
ring atom with an unsaturated bond or is a nitrogen, R4 is
absent, and when A 2 joins a ring atom with an unsaturated
bond and is a nitrogen, both R4 and Rs are absent.
A 3 is carbon or nitrogen, provided that when A 3 joins a
ring atom with an unsaturated bond or is a nitrogen, R 6 is
absent, and when A 3 joins a ring atom with an unsaturated
bond and is a nitrogen, both R 6 and R 7 are absent.
A 4 is carbon or nitrogen, provided that when A 4 joins a
ring atom with an unsaturated bond or is a nitrogen, R 8 is
absent, and when A 4 joins a ring atom with an unsaturated
bond and is a nitrogen, both R 8 and R 9 are absent.
As is carbon or nitrogen, provided that when As joins a
ring atom with an unsaturated bond or is a nitrogen, R 10 is
absent, and when As joins a ring atom with an unsaturated
bond and is a nitrogen, both R 10 and R 11 are absent.
A 6 is carbon or nitrogen, provided that when A 6 joins a
ring atom with an unsaturated bond or is a nitrogen, R 12 is
absent, and when A 6 joins a ring atom with an unsaturated
bond and is a nitrogen, both R 12 and R 13 are absent.
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A 7 is carbon or nitrogen, provided that when A 7 joins a
ring atom with an unsaturated bond or is a nitrogen, R 14 is
absent, and when A 7 joins a ring atom with an unsaturated
bond and is a nitrogen, both R 14 and R 15 are absent.
A 8 is carbon or nitrogen, provided that when A 8 joins a
ring atom with an unsaturated bond or is a nitrogen, R 15 is
absent, and when A 8 joins a ring atom with an unsaturated
bond and is a nitrogen, both R 15 and R 16 are absent.
A 9 is carbon or nitrogen, provided that when A 9 joins a
ring atom with an unsaturated bond or is a nitrogen, R 17 is
absent, and when A 9 joins a ring atom with an unsaturated
bond and is a nitrogen, both R 17 and R 18 are absent.
A IO is carbon or nitrogen, provided that when A IO joins a
ring atom with an unsaturated bond or is a nitrogen, R 19 is
absent, and when A IO joins a ring atom with an unsaturated
bond and is a nitrogen, both R 19 and R 20 are absent.
A 11 is carbon or nitrogen, provided that when A 11 joins a
ring atom with an unsaturated bond or is a nitrogen, R 21 is
absent, and when A 11 joins a ring atom with an unsaturated
bond and is a nitrogen, both R 21 and R 22 are absent.
R3 R4 Rs R6 R7 R8 R9 RIO R11 R12 and R13 or R14
R 1s R' 16 'Rl7' R1s RI9 R2o R21 :mdR22 ~hen present ar~
'
'
' selected
'
' from
' hydrogen,
'
'
each' independently
alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, alkylaryl, substituted alkylaryl, arylalkyl,
substituted arylalkyl, arylalkenyl, substituted arylalkenyl,
arylalkynyl, substituted arylalkynyl, heterocyclic, substituted heterocyclic, halo, cyano, nitro, SOY 1, S0 2Y 1,
S0 20Y 1 or S0 2NHY 1, where Y 1 is selected from hydrogen,
lower alkyl, alkenyl, alkynyl or aryl, and where Y 1 is not
hydrogen in SOY 1 and ifY 1 is alkenyl or alkynyl, the site of
unsaturation is not conjugated with a heteroatom; COY2,
where Y 2 is selected from hydrogen, alkyl, substituted alkyl,
cycloalkyl, substituted cycloalkyl, alkoxy, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted
aryl, alkylaryl, substituted alkylaryl, arylalkyl, substituted
arylalkyl, arylalkenyl, substituted arylalkenyl, arylalkynyl,
substituted arylalkynyl, heterocyclic, or substituted heterocyclic, and where ifY2 comprises alkenyl or alkynyl, the site
of unsaturation is not conjugated with the carbonyl group;
OY3, where Y 3 is selected from hydrogen, alkyl, substituted
alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, substituted
alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl,
alkylaryl, substituted alkylaryl, arylalkyl, substituted arylalkyl, arylalkenyl, substituted arylalkenyl, arylalkynyl, substituted arylalkynyl, acyl, substituted acyl, alkylsulfonyl,
arylsulfonyl, heterocyclic, or substituted heterocyclic, where
if Y 3 comprises alkenyl or alkynyl, the site of unsaturation
is not conjugated with the oxygen; NY4Y 5, where Y 4 and Y 5
are each independently selected from hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, alkenyl,
substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, alkylaryl, substituted alkylaryl, arylalkyl, substituted arylalkyl, arylalkenyl, substituted arylalkenyl, arylalkynyl, substituted arylalkynyl, acyl, substituted acyl,
alkylsulfonyl, arylsulfonyl, heterocyclic, or substituted heterocyclic, where if Y 4 or Y 5 comprises alkenyl or alkynyl,
the site of unsaturation is not conjugated with the nitrogen;
SY6, where Y 6 is selected from hydrogen, alkyl, substituted
alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, substituted
alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl,
alkylaryl, substituted alkylaryl, arylalkyl, substituted arylalkyl, arylalkenyl, substituted arylalkenyl, arylalkynyl, substituted arylalkynyl, heterocyclic, or substituted heterocyclic, and where ifY 6 comprises alkenyl or alkynyl, the site
ofunsaturation is not conjugated with the sulfur; or R5 and

R 6 together with A 2 and A 3, or R 6 and R 8 together with A 3
andA4, or R 16 and R 17 together withA 8 andA9, or R 17 and
R 18 together with A 9 and A IO independently form a three to
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eight member cyclolkane, substituted cycloalkane, cycloalkene, substituted cycloalkene, aryl, substituted aryl, heterocycle with one to three hetero atoms in the ring, or substituted heterocycle with one to three hetero atoms in the ring;
and when all of the bonds to the ring ammonium nitrogen are
saturated, then any ofR3, R4, R5, R 6, R 7, R 8, R 9, RIO, R 11 ,
Rl2, Rl3, R14, R1s, R16, Rl7, R18, R19, R2o, R21 or R22 which
is attached to the ammonium nitrogen is a straight or
branched alkyl group of four carbons or fewer.
In another embodiment, a composition is provided comprising a pharmaceutically acceptable carrier and a compound as described above.
In another embodiment, a method is provided for selectively modulating the function of a nicotinic acetylcholine
receptor comprising administering a therapeutically effective amount of a compound as described above to a mammalian subject in need thereof.
In another embodiment, a method is provided for preventing and/or treating a central nervous system associated
disorder comprising administering a therapeutically effective amount of a compound as described above to a mammalian subject in need thereof.
In another embodiment, a method is provided for preventing and/or treating substance use and/or abuse comprising administering a therapeutically effective amount of a
compound as described above to a mammalian subject in
need thereof.
In another embodiment, a method is provided for preventing and/or treating gastrointestinal tract disorders comprising administering a therapeutically effective amount of a
compound as described above to a mammalian subject in
need thereof.
Other methods, features and advantages of the present
invention will be or become apparent to one with skill in the
art upon examination of the following detailed descriptions.
It is intended that all such additional methods, features and
advantages be included within this description, be within the
scope of the present invention, and be protected by the
accompanying claims.
BRIEF DESCRIPTION OF THE DRAWINGS

45

FIG. 1 shows the concentration dependent inhibition by
compound GZ527B on the effect of nicotine to evoke
[3H]dopamine release.
50
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DETAILED DESCRIPTION OF INVENTION
Before the present compositions and methods are
described, it is to be understood that the invention is not
limited to the particular methodologies, protocols, assays,
and reagents described, as these may vary. It is also to be
understood that the terminology used herein is intended to
describe particular embodiments of the present invention,
and is in no way intended to limit the scope of the present
invention as set forth in the appended claims.
It must be noted that as used herein and in the appended
claims, the singular forms "a," "an," and "the" include plural
references unless the context clearly dictates otherwise.
Unless defined otherwise, all technical and scientific
terms used herein have the same meanings as commonly
understood by one of ordinary skill in the art to which this
invention belongs. All publications cited herein are incorporated herein by reference in their entirety for the purpose

US 9,540,327 B2
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of describing and disclosing the methodologies, reagents,
and tools reported in the publications that might be used in
connection with the invention. Nothing herein is to be
construed as an admission that the invention is not entitled
to antedate such disclosure by virtue of prior invention.
The term "nicotinic acetylcholine receptor" refers to the
endogenous acetylcholine receptor having binding sites for
acetylcholine which also bind to nicotine. The term "nicotinic acetylcholine receptor" includes the term "neuronal
nicotinic acetylcholine receptor."
The terms "subtype of nicotinic acetylcholine receptor,"
and "nicotinic acetylcholine receptor subtype" refer to various subunit combinations of the nicotinic acetylcholine
receptor, and may refer to a particular homomeric or heteromeric complex, or multiple homomeric or heteromeric
complexes.
The term "agonist" refers to a substance which interacts
with a receptor and increases or prolongs a physiological
response (i.e. activates the receptor).
The term "partial agonist" refers to a substance which
interacts with and activates a receptor to a lesser degree than
an agonist.
The term "antagonist" refers to a substance which interacts with and decreases the extent or duration of a physiological response of that receptor.
The terms "disorder," "disease," and "condition" are used
inclusively and refer to any status deviating from normal.
The term "central nervous system associated disorders"
includes any cognitive, neurological, and mental disorders
causing aberrant or pathological neural signal transmission,
such as disorders associated with the alteration of normal
neurotransmitter release in the brain.
The term "lower alkyl" refers to straight or branched
chain alkyl radicals having in the range of 1 to 4 carbon
atoms.
The term "alkyl" refers to straight or branched chain alkyl
radicals having 1 to 19 carbon atoms, and "substituted alkyl"
refers to alkyl radicals further bearing one or more substituents including, but not limited to, hydroxy, alkoxy (of a
lower alkyl group), mercapto (of a lower alkyl group), aryl,
heterocyclic, halogen, trifluoromethyl, cyano, nitro, amino,
carboxyl, carbamate, sulfonyl, and sulfonamide.
The term "cycloalkyl" refers to cyclic ring-containing
moieties containing 3 to 8 carbon atoms, and "substituted
cycloalkyl" refers to cycloalkyl moieties further bearing one
or more substituents as set forth above.
The term "alkenyl" refers to straight or branched chain
hydrocarbyl groups having at least one carbon-carbon
double bond and having 2 to 19 carbon atoms, and "substituted alkenyl" refers to alkenyl groups further bearing one or
more substituents as set forth above.
The term "alkynyl" refers to straight or branched chain
hydrocarbyl moieties having at least one carbon-carbon
triple bond and having 2 to 19 carbon atoms, and "substituted alkynyl" refers to alkynyl moieties further bearing one
or more substituents as set forth above.
The term "aryl" refers to aromatic groups having 6 to 24
carbon atoms, and "substituted aryl" refers to aryl groups
further bearing one or more substituents as set forth above.
The term "alkylaryl" refers to alkyl-substituted aryl
groups, and "substituted alkylaryl" refers to alkylaryl groups
further bearing one or more substituents as set forth above.
The term "arylalkyl" refers to aryl-substituted alkyl
groups, and "substituted arylalkyl" refers to arylalkyl groups
further bearing one or more substituents as set forth above.

The term "arylalkenyl" refers to aryl-substituted alkenyl
groups, and "substituted arylalkenyl" refers to arylalkenyl
groups further bearing one or more substituents as set forth
above.
The term "arylalkynyl" refers to aryl-substituted alkynyl
groups, and "substituted arylalkynyl" refers to arylalkynyl
groups further bearing one or more substituents as set forth
above.
The term "heterocyclic" refers to cyclic moieties containing one or more heteroatoms as part of the ring structure and
having 3 to 24 carbon atoms, and "substituted heterocyclic"
refers to heterocyclic moieties further bearing one or more
substituents as set forth above.
The term "acyl" refers to alkyl-carbonyl groups, and
"substituted acyl" refers to acyl groups further bearing one
or more substituents as set forth above.
The term "halogen" refers to fluoride, chloride, bromide
or iodide groups.
It is understood that in all substituted groups defined
above, polymers arrived at by defining substituents with
further substituents to themselves (e.g. substituted aryl having a substituted aryl group as a substituent which is itself
substituted with a substituted aryl group, etc.) are not
intended for inclusion herein. In such cases, the maximum
number of such substituents is three. That is to say that each
of the above definitions is constrained by a limitation that,
for example, substituted aryl groups are limited to -substituted aryl-(substituted aryl)-substituted aryl.
Compounds of the present invention are tris-quaternary
ammonium salts corresponding to Formula (I):
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X
and X
are each independently an organic or
inorganic anion.
R is chosen from the group consisting of alkyl, substituted
alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, substituted
alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl,
arylalkyl, substituted arylalkyl, arylalkenyl, substituted arylalkenyl, arylalkynyl, substituted arylalkynyl, heterocyclic,
substituted heterocyclic, alkoxy, alkylamine and thioalkyl.
R 1 and R 2 are each independently five or six membered
rings as shown in formulas (IIA) and (liB), wherein each
ring of R 1 and R 2 has one, two or three nitrogen atoms, each
ring of R 1 and R 2 has one quaternized nitrogen, and the ring
atoms from R 1 and R 2 which are attached toR cannot both
be nitrogen atoms.

(!lA)

55

(liB)

60

65

A 1 is carbon or nitrogen, provided that when A 1 joins a
ring atom with an unsaturated bond or is a nitrogen, R 3 is
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absent, and when A 1 joins a ring atom with an unsaturated
bond and is a nitrogen, both R3 and R4 are absent.
A 2 is carbon or nitrogen, provided that when A 2 joins a
ring atom with an unsaturated bond or is a nitrogen, R4 is
absent, and when A 2 joins a ring atom with an unsaturated
bond and is a nitrogen, both R4 and Rs are absent.
A 3 is carbon or nitrogen, provided that when A 3 joins a
ring atom with an unsaturated bond or is a nitrogen, R 6 is
absent, and when A 3 joins a ring atom with an unsaturated
bond and is a nitrogen, both R 6 and R7 are absent.
A4 is carbon or nitrogen, provided that when A4 joins a
ring atom with an unsaturated bond or is a nitrogen, R 8 is
absent, and when A4 joins a ring atom with an unsaturated
bond and is a nitrogen, both R 8 and R9 are absent.
As is carbon or nitrogen, provided that when As joins a
ring atom with an unsaturated bond or is a nitrogen, RIO is
absent, and when As joins a ring atom with an unsaturated
bond and is a nitrogen, both RIO and R 11 are absent.
A 6 is carbon or nitrogen, provided that when A 6 joins a
ring atom with an unsaturated bond or is a nitrogen, R 12 is
absent, and when A 6 joins a ring atom with an unsaturated
bond and is a nitrogen, both R 12 and R 13 are absent.
A 7 is carbon or nitrogen, provided that when A 7 joins a
ring atom with an unsaturated bond or is a nitrogen, R 14 is
absent, and when A 7 joins a ring atom with an unsaturated
bond and is a nitrogen, both R 14 and R 1s are absent.
A 8 is carbon or nitrogen, provided that when A 8 joins a
ring atom with an unsaturated bond or is a nitrogen, R 1s is
absent, and when A 8 joins a ring atom with an unsaturated
bond and is a nitrogen, both R 1s and R 16 are absent.
A 9 is carbon or nitrogen, provided that when A 9 joins a
ring atom with an unsaturated bond or is a nitrogen, R 17 is
absent, and when A 9 joins a ring atom with an unsaturated
bond and is a nitrogen, both R 17 and R 18 are absent.
A IO is carbon or nitrogen, provided that when A 10 joins a
ring atom with an unsaturated bond or is a nitrogen, R 19 is
absent, and when A IO joins a ring atom with an unsaturated
bond and is a nitrogen, both R 19 and R 20 are absent.
A 11 is carbon or nitrogen, provided that when A 11 joins a
ring atom with an unsaturated bond or is a nitrogen, R 21 is
absent, and when A 11 joins a ring atom with an unsaturated
bond and is a nitrogen, both R 21 and R 22 are absent.
R3, R4, Rs, R 6, R7, R 8, R9, RIO, R 11 , R 12 , and R 13 or R 14 ,
R 1s, R 16 , R 17 , R 18 , R 19 , R 20 , R 21 , and R 22 , when present, are
each independently selected from hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, alkylaryl, substituted alkylaryl, arylalkyl,
substituted arylalkyl, arylalkenyl, substituted arylalkenyl,
arylalkynyl, substituted arylalkynyl, heterocyclic, substituted heterocyclic, halo, cyano, nitro, SOY 1, S0 2Y 1,
S0 20Y 1 or S0 2NHY 1, where Y 1 is selected from hydrogen,
lower alkyl, alkenyl, alkynyl or aryl, and where Y 1 is not
hydrogen in SOY 1 and ifY 1 is alkenyl or alkynyl, the site of
unsaturation is not conjugated with a heteroatom; COY2,
where Y 2 is selected from hydrogen, alkyl, substituted alkyl,
cycloalkyl, substituted cycloalkyl, alkoxy, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted
aryl, alkylaryl, substituted alkylaryl, arylalkyl, substituted
arylalkyl, arylalkenyl, substituted arylalkenyl, arylalkynyl,
substituted arylalkynyl, heterocyclic, or substituted heterocyclic, and where ifY2 comprises alkenyl or alkynyl, the site
of unsaturation is not conjugated with the carbonyl group;
OY3, where Y 3 is selected from hydrogen, alkyl, substituted
alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, substituted
alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl,
alkylaryl, substituted alkylaryl, arylalkyl, substituted arylal-
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kyl, arylalkenyl, substituted arylalkenyl, arylalkynyl, substituted arylalkynyl, acyl, substituted acyl, alkylsulfonyl,
arylsulfonyl, heterocyclic, or substituted heterocyclic, where
if Y 3 comprises alkenyl or alkynyl, the site of unsaturation
is not conjugated with the oxygen; NY4Ys, where Y4 and ys
are each independently selected from hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, alkenyl,
substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, alkylaryl, substituted alkylaryl, arylalkyl, substituted arylalkyl, arylalkenyl, substituted arylalkenyl, arylalkynyl, substituted arylalkynyl, acyl, substituted acyl,
alkylsulfonyl, arylsulfonyl, heterocyclic, or substituted heterocyclic, where if Y4 or ys comprises alkenyl or alkynyl,
the site of unsaturation is not conjugated with the nitrogen;
SY6, where Y 6 is selected from hydrogen, alkyl, substituted
alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, substituted
alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl,
alkylaryl, substituted alkylaryl, arylalkyl, substituted arylalkyl, arylalkenyl, substituted arylalkenyl, arylalkynyl, substituted arylalkynyl, heterocyclic, or substituted heterocyclic, and where ifY 6 comprises alkenyl or alkynyl, the site
ofunsaturation is not conjugated with the sulfur; or Rs and
R 6 together with A 2 and A 3, or R 6 and R 8 together with A 3
andA4, or R 16 and R 17 together withA 8 andA9, or R 17 and
R 18 together with A 9 and A IO independently form a three to
eight member cyclolkane, substituted cycloalkane, cycloalkene, substituted cycloalkene, aryl, substituted aryl, heterocycle with one to three hetero atoms in the ring, or substituted heterocycle with one to three hetero atoms in the ring;
and when all of the bonds to the ring ammonium nitrogen are
saturated, then any ofR3, R4, Rs, R 6, R7, R 8, R9, RIO, R 11 ,
Rl2, Rl3, R14' R1s, R16' Rl7, R18' R19' R2o, R21 or R22 which
is attached to the ammonium nitrogen is a straight or
branched alkyl group of four carbons or fewer.
For example, R 1 and R 2 include pyrrole, pyrrolidine,
pyrazole, imidazole, 1,2,3-triazole, 1,2,4-triazole, pyridine,
piperidine, quinoline, tetrahydroquinoline, isoquinoline, tetrahydroisoquinoline, pyrazine, piperazine, pyridazine, and
triazine.
As another example, R3, R4, Rs, R 6, R7, R 8, R9, RIO, R 11 ,
Rl2, Rl3, R14' R1s, R16' Rl7, R18' R19' R2o, R21 and R22,
include hydrogen, methyl, ethyl, propyl, butyl, trifluoromethyl, pyrrolidine, N-alkyl pyrrolidine (for example where
the alkyl chain is methyl, ethyl or propyl), unsaturated
pyrrolidine, unsaturated N-alkyl pyrrolidine (for example
where the alkyl chain is methyl, ethyl or propyl), aziridine,
N-methyl aziridine, azetidine, N-methyl azetidine, unsaturated azetidine, unsaturated N-methyl azetidine, piperidine,
N-methyl piperidine, unsaturated piperidine, unsaturated
N-methyl piperidine, azepane, N-methyl azepane, unsaturated azepane, unsaturated N-methyl azepane, azocane,
N-methyl azocane, unsaturated azocane, unsaturated
N-methyl azocane, 1-aza-bicyclo [3.2.1] octane, 1-aza-bicyclo [2.2.1] heptane, 8-methyl-8-aza-bicyclo [3.2.1]
octane,
1-aza-tricyclo [3.3.1.1 3.7] decane, methyl
cycloalkyl, methyl substituted cycloalkyl, methyl pyrrolidine, methyl N-alkyl pyrrolidine (for example where the
alkyl chain is methyl, ethyl or propyl), methyl unsaturated
pyrrolidine, methyl unsaturated N-alkyl pyrrolidine (for
example where the alkyl chain is methyl, ethyl or propyl),
methyl aziridine, methyl N-methyl aziridine, methyl azetidine, methyl N-methyl azetidine, methyl unsaturated azetidine, methyl unsaturated N-methyl azetidine, methyl piperidine, methyl N-methyl piperidine, methyl unsaturated
piperidine, methyl unsaturated N-methyl piperidine, methyl
azepane, methyl N-methyl azepane, methyl unsaturated
azepane, methyl unsaturated N-methyl azepane, methyl azo-
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cane, methyl N-methyl azocane, methyl unsaturated azocane, methyl unsaturated N-methyl azocane, methyl-1-azabicyclo [3.2.1] octane, methyl-1-aza-bicyclo [2.2.1]
heptane, 8-methyl-8-aza-bicyclo [3 .2.1] octane, and methyl1-aza-tricyclo [3.3.1.1 3 •7 ] decane.
As a further example, when R5 and R6 together with A 2
andA3 , orR 6 andR 8 togetherwithA3 andA4 , orR 16 andR 17
together with A 8 andA9 , orR 17 and R 19 together withA9 and
A IO independently form a three to eight-membered ring, that
ring may be a heterocycle containing up to three hetero
atoms (for example nitrogen, oxygen or sulfur) in the ring,
and further may be substituted with one or more substituents. For example, possible rings include benzene, pyridine,
pyran, indene, isoindene, benzofuran, isobenzofuran, benzo
[b ]thiophene, benzo[ c]thiophene, indole, indolenine, isoindole, cyclopental[b ]pyridine, pyrano[3,4-b ]pynrole, indazole, indoxazine, benzoxazole, anthranil naphthalene,
tetralin, decalin, chromene, coumarin, chroman-4-one, isocoumarin, isochromen-3-one, quinoline, isoquinoline, cinnoline, quinazoline, naphthyrdine, pyrido[3,4-b]-pyridine,
pyridol[3,2-b ]pyridine, pyrido[ 4,3,-b ]-pyridine, benzoxazine, anthracene, phenanthrene, phenalene, fluorene, carazole, xanthene, acnidine, octahydro-[l]pyridine, 1-methyloctahydro-[ !]pyridine,
octahydroindole,
1-methyloctahydro-indole, octahydro-cyclopenta[b]pyrrole,
1-methyloctahydro-cyclopenta[b]pyrrole, decahydroquinoline, and 1-methyldecahydroquinoline.
X 18 and X 28 , for example, include F-, Cl-, Br-, I-,
N0 2 -, HS04 -, S04 -, HP04 -, PO/-, methanesulfonate,
trifluromethane sulfate, p-toluenesulfonate, benzenesulfonate, salicylate, proprionate, ascorbate, aspartate, fumarate, galactarate, maleate, citrate, glutamate, glycolate, lactate, malate, maleate, tartrate, oxalate, succinate, or similar
pharmaceutically acceptable organic acid addition salts,
including the pharmaceutically acceptable salts listed in the
Journal of Pharmaceutical Sciences volume 66, page 2,
1977, which are hereby incorporated by reference. The
above salt forms may be in some cases hydrates or solvates
with alcohols and other solvents.
In a compound of Formula (I), preferably R 1 and R 2 are
substituted, six-membered, aromatic rings. More preferably,
R 1 and R 2 are substituted pyridinium rings, wherein A\ A 2 ,
A 3 or A 4 is nitrogen.
In a compound of Formula (I), preferably R3 is absent.
In a compound of Formula (I), preferably R4 , R5 , R 6 , R7 ,
8
R , R9 , RIO, R 11 , R 12 or R 13 is absent or is hydrogen, alkyl
or 1-methyl-2-pyrrolidinyl. More preferably, R4 , R5 , R 6 , R7 ,
R 8 , R9 , RIO, R 11 , R 12 or R 13 is absent or is hydrogen, methyl
or 1-methyl-2-pyrrolidinyl.
In a compound of Formula (I), preferably R is alkyl. More
preferably, R is -(CH 2 ) 12- .
In a compound of Formula (I), preferably X 18 and X 28
are halogens. More preferably, X 18 and X 28 are bromide or
iodide.
In one embodiment, the compound of Formula (I) is
defined wherein R is -(CH 2 ) 12- , R 1 and R 2 are pyridinium
rings, A 2 is nitrogen, R5 is methyl, and X 1 and X 2 are
bromide or iodide.
In another embodiment, the compound of Formula (I) is
defined wherein R is -(CH 2 ) 12- , R 1 and R 2 are pyridinium
rings, A 3 is nitrogen, R7 is methyl, R 11 is hydrogen or
methyl, and X 1 and X 2 are bromide or iodide.
In another embodiment, the compound of Formula (I) is
defined wherein R is -(CH 2 ) 12- , R 1 and R 2 are pyridinium
rings, A 4 is nitrogen, R9 is methyl, and X 1 and X 2 are
bromide or iodide.

In another embodiment, the compound of Formula (I) is
defined wherein R is -(CH 2 ) 12- , R 1 and R 2 are pyridinium
rings; and wherein for R\ A 3 is nitrogen, R7 is methyl, R 11
is hydrogen or methyl, and X 1 is bromide or iodide; and
wherein for R 2 , A 1 is nitrogen, R 7 and R 11 is hydrogen,
methyl or 1-methyl-2-pyrrolidinyl, and X 2 is bromide or
iodide.
Exemplary compounds of the present invention include:
N,N'-dimethyl-2,2'-(1, 12-dodecanediyl)bispyridinium diiodide;
N,N'-dimethyl-3,3'-(1, 12-dodecanediyl)bispyridinium diiodide;
N,N'-dimethyl-4,4'-(1, 12-dodecanediyl)bispyridinium diiodide;
N,N'-dimethyl-3,3'-(1, 12-dodecanediyl)bis-5-methylpyridinium diiodide;
1-methyl-3-(12-(3-methylpyridin-1-ium-1-yl)dodecyl)pyridin-1-ium mono-bromide mono-iodide;
3,5-dimethyl-1-(12-(1-methylpyridin-1-ium-3-yl)dodecyl)
pyridin-1-ium mono-bromide mono-iodide;
(S)-1-methyl-3-(12-(3-(1-methylpyrrolidin-2-yl)pyridin-1ium-1-yl)dodecyl)pyridin-1-ium mono-bromide monoiodide; and
1-methyl-3-(12-(pyridin-1-ium-1-yl)dodecyl)pyridin-1-ium
mono-bromide mono-iodide.
The compounds of the present invention may contain one
or more stereocenters. The invention includes all possible
diastereomers and all enantiomeric forms as well as racemic
mixtures. The compounds can be separated into substantially optically pure compounds.
The compounds of the invention are nicotinic acetylcholine receptor agents. Thus, they may augment or inhibit
3
3
[ H]nicotine binding, [ H]MLA binding, evoke or inhibit
neurotransmitter release, and/or evoke or inhibit the flux of
ions through the nicotinic receptor.
Moreover, the compounds of the invention may act either
at presynaptic sites or postsynaptic sites, for example, at a
postsynaptic acetylcholine receptor containing an a7 subunit. When acting at a postsynaptic site, neurotransmitter
release per se is not altered. Rather, the compounds of the
invention may act by interacting with a postsynaptic acetylcholine receptor to change the membrane potential of the
cell, thereby increasing or decreasing the likelihood of firing
an action potential. Alternatively, interaction of a compound
of the invention with a postsynaptic acetylcholine receptor
may result in the alteration of one or more second messenger
systems within the cell so as to decrease or increase the
nicotinic cholinergic response.
In one embodiment, the present invention relates to a
method for selectively modulating the function of a nicotinic
acetylcholine receptor comprising administering to a mammalian subject in need thereof a therapeutically effective
amount of a compound of Formula (I). In such a method, the
compound of Formula (I) may selectively bind to one or
more subtypes of nicotinic acetylcholine receptor. The compound of Formula (I) may act as an against or partial agonist
of nicotinic acetylcholine receptor function. Hence the compound of Formula (I) may increase or prolong the release of
a neurotransmitter from a central nervous system tissue. The
neurotransmitter affected may include dopamine, norepinephrine, serotonin, gamma-aminobutryic acid, or glutamate. Alternatively, the compound of Formula (I) may act as
an antagonist of nicotinic acetylcholine receptor function.
Hence the compound of Formula (I) may decrease the extent
or duration of the release of a neurotransmitter from a central
nervous system tissue. In this regard, the compound of
Formula (I) may act by decreasing stimulant-evoked neu-
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rotransmitter release. The neurotransmitter affected may
include dopamine, norepinephrine, serotonin, gamma-aminobutryic acid, or glutamate. Alternatively, the compound of
Formula (I) may act by interacting with a postsynaptic
acetylcholine receptor to change the membrane potential of
the cell thereby increasing or decreasing the likelihood of
firing an action potential, or to alter one or more second
messenger systems within the cell so as to decrease or
increase the nicotinic cholinergic response.
In another embodiment, the present invention is directed
to a method for preventing and/or treating a central nervous
system associated disorder comprising administering to a
mammalian subject in need thereof a therapeutically effective amount of a compound of Formula (I). In such a
method, the compound of Formula (I) may selectively bind
to one or more subtypes of nicotinic acetylcholine receptor.
The compound of Formula (I) may act as an against or
partial agonist of nicotinic acetylcholine receptor function.
Hence the compound of Formula (I) may increase or prolong
the release of a neurotransmitter from a central nervous
system tissue. The neurotransmitter affected may include
dopamine, norepinephrine, serotonin, gamma-aminobutryic
acid, or glutamate. Alternatively, the compound of Formula
(I) may act as an antagonist of nicotinic acetylcholine
receptor function. Hence the compound of Formula (I) may
decrease the extent or duration of the release of a neurotransmitter from a central nervous system tissue. In this regard,
the compound of Formula (I) may act by decreasing stimulant-evoked neurotransmitter release. The neurotransmitter
affected may include dopamine, norepinephrine, serotonin,
gamma-aminobutryic acid, or glutamate. Alternatively, the
compound of Formula (I) may act by interacting with a
postsynaptic acetylcholine receptor to change the membrane
potential of the cell thereby increasing or decreasing the
likelihood of firing an action potential, or to alter one or
more second messenger systems within the cell so as to
decrease or increase the nicotinic cholinergic response.
Central nervous system disorders which may be treated
according to the method of the present invention include
Alzheimer's disease, dementia, cognitive dysfunctions (including disorders of attention, focus and concentration),
attention deficit disorders, affective disorders, extrapyramidal motor function disorders, Parkinson's disease, progressive supramolecular palsy, Huntington's disease, Gilles de Ia
Tourette syndrome, tardive dyskinesia, neuroendocrine disorders, dysregulation of food intake, disorders of nociception, pain, mood and emotional disorders, depression, panic
anxiety, psychosis, schizophrenia, or epilepsy.
In yet another embodiment, the present invention is
directed to a method for preventing and/or treating substance
use and/or abuse comprising administering to a mmalian
subject in need thereof a therapeutically effective amount of
a compound of Formula (I). In such a method, the compound
of Formula (I) may selectively bind to one or more subtypes
of nicotinic acetylcholine receptor. The compound of Formula (I) may act as an against or partial agonist of nicotinic
acetylcholine receptor function. Hence the compound of
Formula (I) may increase or prolong the release of a neurotransmitter from a central nervous system tissue. The
neurotransmitter affected may include dopamine, norepinephrine, serotonin, gma-aminobutryic acid, or glutamate. Alternatively, the compound of Formula (I) may act as
an antagonist of nicotinic acetylcholine receptor function.
Hence the compound of Formula (I) may decrease the extent
or duration of the release of a neurotransmitter from a central
nervous system tissue. In this regard, the compound of
Formula (I) may act by decreasing stimulant-evoked neu-

rotransmitter release. The neurotransmitter affected may
include dopamine, norepinephrine, serotonin, gamma-aminobutryic acid, or glutamate. Alternatively, the compound of
Formula (I) may act by interacting with a postsynaptic
acetylcholine receptor to change the membrane potential of
the cell thereby increasing or decreasing the likelihood of
firing an action potential, or to alter one or more second
messenger systems within the cell so as to decrease or
increase the nicotinic cholinergic response.
The conditions of substance use and/or abuse treated
according to the method of the present invention include
nicotine abuse (including use in smoking cessation therapy),
nicotine intoxication, amphetamine abuse, methamphetamine abuse, MDMA (methylenedioxymethamphetamine)
abuse, methylphenidate abuse, cocaine abuse, or alcohol
abuse.
In another embodiment, the present invention is directed
to a method for preventing and/or treating gastrointestinal
tract disorders comprising administering to a mmalian
subject in need thereof a therapeutically effective amount of
a compound of Formula (I). In such a method, the compound
of Formula (I) may selectively bind to one or more subtypes
of nicotinic acetylcholine receptor. The compound of Formula (I) may act as an agonist or partial agonist of nicotinic
acetylcholine receptor function. Hence the compound of
Formula (I) may increase or prolong the release of a neurotransmitter from a central nervous system tissue, or may
increase or prolong the release of a neurotransmitter from a
peripheral nervous system tissue, or may act directly on a
gastrointestinal tract tissue. The neurotransmitter affected
may include dopamine, norepinephrine, serotonin, gammaaminobutryic acid, or glutamate. Alternatively, the compound of Formula (I) may act as an antagonist of nicotinic
acetylcholine receptor function. Hence the compound of
Formula (I) may decrease the extent or duration of the
release of a neurotransmitter from a central nervous system
tissue, or may decrease the extent or duration of the release
of a neurotransmitter from a peripheral nervous system
tissue, or may act directly on a gastrointestinal tract tissue.
In this regard, the compound of Formula (I) may act by
decreasing stimulant-evoked neurotransmitter release. The
neurotransmitter affected may include dopamine, norepinephrine, serotonin, gamma-aminobutryic acid, or glutamate. Alternatively, the compound of Formula (I) may act by
interacting with a postsynaptic acetylcholine receptor to
change the membrane potential of the cell thereby increasing
or decreasing the likelihood of firing an action potential, or
to alter one or more second messenger systems within the
cell so as to decrease or increase the nicotinic cholinergic
response.
Gastrointestinal disorders which may be treated according
to the method of the present invention include irritable
bowel syndrome, colitis, diarrhea, constipation, gastric acid
secretion or ulcers.
The compounds of the present invention can be delivered
directly or in pharmaceutical compositions along with suitable carriers or excipients, as is well known in the art. For
example, a pharmaceutical composition of the invention
may include a conventional additive, such as a stabilizer,
buffer, salt, preservative, filler, flavor enhancer and the like,
as known to those skilled in the art. Exemplary buffers
include phosphates, carbonates, citrates and the like. Exemplary preservatives include EDTA, EGTA, BHA, BHT and
the like.
An effective amount of such agents can readily be determined by routine experimentation, as can the most effective
and convenient route of administration and the most appro-
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priate formulation. Various formulations and drug delivery
systems are available in the art. See, e.g., Gennaro, A. R., ed.
(1995) Remington's Pharmaceutical Sciences.
Suitable routes of administration may, for example,
include oral, rectal, transmucosal, nasal, or intestinal administration and parenteral delivery, including intramuscular,
subcutaneous, intramedullary injections, as well as intrathecal, direct intraventricular, intravenous, intraperitoneal,
intranasal, or intraocular injections. In addition, the agent or
composition thereof may be administered sublingually or via
a spray, including a sublingual tablet or a sublingual spray.
The agent or composition thereof may be administered in a
local rather than a systemic marmer. For example, a suitable
agent can be delivered via injection or in a targeted drug
delivery system, such as a depot or sustained release formulation.
The pharmaceutical compositions of the present invention
may be manufactured by any of the methods well-known in
the art, such as by conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifYing, encapsulating, entrapping, or lyophilizing processes. As noted above,
the compositions of the present invention can include one or
more physiologically acceptable carriers such as excipients
and auxiliaries that facilitate processing of active molecules
into preparations for pharmaceutical use.
Proper formulation is dependent upon the route of administration chosen. For injection, for example, the composition
may be formulated in aqueous solutions, preferably in
physiologically compatible buffers such as Hanks' solution,
Ringer's solution, or physiological saline buffer. For transmucosal or nasal administration, penetrants appropriate to
the barrier to be permeated are used in the formulation. Such
penetrants are generally known in the art. In a preferred
embodiment of the present invention, the present compounds are prepared in a formulation intended for oral
administration. For oral administration, the compounds can
be formulated readily by combining the active compounds
with pharmaceutically acceptable carriers well known in the
art. Such carriers enable the compounds of the invention to
be formulated as tablets, pills, dragees, capsules, liquids,
gels, syrups, slurries, suspensions and the like, for oral
ingestion by a subject. The compounds may also be formulated in rectal compositions such as suppositories or retention enemas, e.g., containing conventional suppository bases
such as cocoa butter or other glycerides.
Pharmaceutical preparations for oral use can be obtained
as solid excipients, optionally grinding a resulting mixture,
and processing the mixture of granules, after adding suitable
auxiliaries, if desired, to obtain tablets or dragee cores.
Suitable excipients are, in particular, fillers such as sugars,
including lactose, sucrose, marmitol, or sorbitol; cellulose
preparations such as, for example, maize starch, wheat
starch, rice starch, potato starch, gelatin, gum tragacanth,
methyl cellulose, hydroxypropylmethyl-cellulose, sodium
carboxymethylcellulose,
and/or
polyvinylpyrrolidone
(PVP). If desired, disintegrating agents may be added, such
as the cross-linked polyvinyl pyrrolidone, agar, or alginic
acid or a salt thereof such as sodium alginate. Also, wetting
agents such as sodium dodecyl sulfate may be included.
Dragee cores are provided with suitable coatings. For this
purpose, concentrated sugar solutions may be used, which
may optionally contain gum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, and/or titanium
dioxide, lacquer solutions, and suitable organic solvents or
solvent mixtures. Dyestuffs or pigments may be added to the
tablets or dragee coatings for identification or to characterize
different combinations of active compound doses.

Pharmaceutical preparations for oral administration
include push-fit capsules made of gelatin, as well as soft,
sealed capsules made of gelatin and a plasticizer, such as
glycerol or sorbitol. The push-fit capsules can contain the
active ingredients in admixture with filler such as lactose,
binders such as starches, and/or lubricants such as talc or
magnesium stearate and, optionally, stabilizers. In soft capsules, the active compounds may be dissolved or suspended
in suitable liquids, such as fatty oils, liquid paraffin, or liquid
polyethylene glycols. In addition, stabilizers may be added.
All formulations for oral administration should be in dosages suitable for such administration.
In one embodiment, the compounds of the present invention can be administered transdermally, such as through a
skin patch, or topically. In one aspect, the transdermal or
topical formulations of the present invention can additionally comprise one or multiple penetration enhancers or other
effectors, including agents that enhance migration of the
delivered compound. Transdermal or topical administration
could be preferred, for example, in situations in which
location specific delivery is desired.
For administration by inhalation, the compounds for use
according to the present invention are conveniently delivered in the form of an aerosol spray presentation from
pressurized packs or a nebulizer, with the use of a suitable
propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide, or
any other suitable gas. In the case of a pressurized aerosol,
the appropriate dosage unit may be determined by providing
a valve to deliver a metered amount. Capsules and cartridges
of, for example, gelatin, for use in an inhaler or insufflator
may be formulated. These typically contain a powder mix of
the compound and a suitable powder base such as lactose or
starch.
Compositions formulated for parenteral administration by
injection, e.g., by bolus injection or continuous infusion can
be presented in unit dosage form, e.g., in ampoules or in
multi-dose containers, with an added preservative. The
compositions may take such forms as suspensions, solutions, or emulsions in oily or aqueous vehicles, and may
contain formulatory agents such as suspending, stabilizing
and/or dispersing agents. Formulations for parenteral administration include aqueous solutions or other compositions in
water-soluble form.
Suspensions of the active compounds may also be prepared as appropriate oily injection suspensions. Suitable
lipophilic solvents or vehicles include fatty oils such as
sesame oil and synthetic fatty acid esters, such as ethyl
oleate or triglycerides, or liposomes. Aqueous injection
suspensions may contain substances that increase the viscosity of the suspension, such as sodium carboxymethyl
cellulose, sorbitol, or dextran. Optionally, the suspension
may also contain suitable stabilizers or agents that increase
the solubility of the compounds to allow for the preparation
of highly concentrated solutions. Alternatively, the active
ingredient may be in powder form for constitution with a
suitable vehicle, e.g., sterile pyrogen-free water, before use.
As mentioned above, the compositions of the present
invention may also be formulated as a depot preparation.
Such long acting formulations may be administered by
implantation (for example, subcutaneously or intramuscularly) or by intramuscular injection. Thus, for example, the
present compounds may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion
in an acceptable oil) or ion exchange resins, or as sparingly
soluble derivatives, for example, as a sparingly soluble salt.
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Suitable carriers for the hydrophobic molecules of the
invention are well known in the art and include co-solvent
systems comprising, for example, benzyl alcohol, a nonpolar
surfactant, a water-miscible organic polymer, and an aqueous phase. The co-solvent system may be the VPD cosolvent system. VPD is a solution of3% w/v benzyl alcohol,
8% w/v of the nonpolar surfactant polysorbate 80, and 65%
w/v polyethylene glycol300, made up to volume in absolute
ethanol. The VPD co-solvent system (VPD:5W) consists of
VPD diluted 1:1 with a 5% dextrose in water solution. This
co-solvent system is effective in dissolving hydrophobic
compounds and produces low toxicity upon systemic administration. Naturally, the proportions of a co-solvent system
may be varied considerably without destroying its solubility
and toxicity characteristics. Furthermore, the identity of the
co-solvent components may be varied. For example, other
low-toxicity nonpolar surfactants may be used instead of
polysorbate 80, the fraction size of polyethylene glycol may
be varied, other biocompatible polymers may replace polyethylene glycol, e.g., polyvinyl pyrrolidone, and other sugars or polysaccharides may substitute for dextrose.
Alternatively, other delivery systems for hydrophobic
molecules may be employed. Liposomes and emulsions are
well known examples of delivery vehicles or carriers for
hydrophobic drugs. Liposomal delivery systems are discussed above in the context of gene-delivery systems. Certain organic solvents such as dimethylsulfoxide also may be
employed, although usually at the cost of greater toxicity.
Additionally, the compounds may be delivered using sustained-release systems, such as semi-permeable matrices of
solid hydrophobic polymers containing the effective amount
of the composition to be administered. Various sustainedrelease materials are established and available to those of
skill in the art. Sustained-release capsules may, depending
on their chemical nature, release the compounds for a few
weeks up to over 100 days. Depending on the chemical
nature and the biological stability of the therapeutic reagent,
additional strategies for stabilization may be employed.
For any composition used in the present methods of
treatment, a therapeutically effective dose can be estimated
initially using a variety of techniques well known in the art.
For example, in a cell culture assay, a dose can be formulated in animal models to achieve a circulating concentration
range that includes the IC 50 as determined in cell culture.
Dosage ranges appropriate for human subjects can be determined, for example, using data obtained from cell culture
assays and other animal studies.
A therapeutically effective dose of an agent refers to that
amount of the agent that results in amelioration of symptoms
or a prolongation of survival in a subject. Toxicity and
therapeutic efficacy of such molecules can be determined by
standard pharmaceutical procedures in cell cultures or
experimental animals, e.g., by determining the LD 50 (the
dose lethal to 50% of the population) and the ED 5 0 (the dose
therapeutically effective in 50% of the population). The dose
ratio of toxic to therapeutic effects is the therapeutic index,
which can be expressed as the ratio LD 50 /ED 50 . Agents that
exhibit high therapeutic indices are preferred.
Dosages preferably fall within a range of circulating
concentrations that includes the ED 50 with little or no
toxicity. Dosages may vary within this range depending
upon the dosage form employed and the route of administration utilized. The exact formulation, route of administration, and dosage should be chosen, according to methods
known in the art, in view of the specifics of a subject's
condition.
The amount of agent or composition administered will, of
course, be dependent on a variety of factors, including the
sex, age, and weight of the subject being treated, the severity

of the afl.liction, the manner of administration, and the
judgment of the prescribing physician.
The present compositions may, if desired, be presented in
a pack or dispenser device containing one or more unit
dosage forms containing the active ingredient. Such a pack
or device may, for example, comprise metal or plastic foil,
such as a blister pack. The pack or dispenser device may be
accompanied by instructions for administration. Compositions comprising a compound of the invention formulated in
a compatible pharmaceutical carrier may also be prepared,
placed in an appropriate container, and labeled for treatment
of an indicated condition.
These and other embodiments of the present invention
will readily occur to those of ordinary skill in the art in view
of the disclosure herein, and are specifically contemplated.
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The invention is further understood by reference to the
following examples, which are intended to be purely exemplary of the invention. The present invention is not limited
in scope by the exemplified embodiments, which are
intended as illustrations of single aspects of the invention
only. Any methods that are functionally equivalent are
within the scope of the invention. Various modifications of
the invention in addition to those described herein will
become apparent to those skilled in the art from the foregoing description. Such modifications fall within the scope
of the appended claims.
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LDA (2M) (20 mL, 40.00 mmol) was added dropwise to
a solution of 2-picoline (3.73 g, 40.00 mmol) in THF (60
mL) at -78° C. The mixture was stirred for 30 min and then
1,10-diiododecane (6.31 g, 16.00 mmol) in THF (10 mL)
was added dropwise. The resulting mixture was warmed to
room temperature and stirred for 4 hrs. 50% saturated
NH4 Cl was added to the reaction mixture. The aqueous
phase was extracted with ethylacetate (40 mLx2), and the
combined organic liquors were washed with 50% saturated
brine (40 mLx3) and saturated brine (40 mL ), dried over
anhydrous Na2 S04 , and concentrated under reduced pressure. The crude product was purified by column chromatography (hexanes:ethylacetate 2:1 to 1:1) to afford 3.75 g of
the title compound. Yield: 72%. 1 H NMR (300 MHz,
CDC1 3 ) ll 1.13-1.42 (m, 16H), 1.60-1.81 (m, 4H), 2.78 (t,
1=7.8 Hz, 4H), 7.08 (ddd, 1=7.5, 5.1, 0.6 Hz, 2H), 7.13 (d,
1=7.5 Hz, 2H), 7.57 (dt, 1=7.5, 1.8 Hz, 2H), 8.52 (dd, 1=5.1,
0.6 Hz, 2H) ppm; 13 C NMR (75 MHz, CDC1 3 ) ll29.7, 29.75,
29.8, 29.9, 30.2, 38.7, 120.9, 122.8, 136.3, 149.2, 162.5
ppm.
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Example 2

Example 4

Preparation of N,N'-dimethyl-2,2'-(1,12-dodecanediyl)bispyridinium diiodide

Preparation of N,N'-dimethyl-3,3'-(1 ,12-dodecanediyl)bispyridinium diiodide
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2,2'-(1,12-Dodecanediyl)bispyridine (370 mg, 1.14
mmol) was dissolved in acetone (15 mL). Methyl iodide
(1.62 g, 11.40 mmol) was added and the mixture was stirred
for 48 hrs at room temperature. The precipitate was filtered
and washed with diethyl ether. The obtained pale yellow
solid was dried under vacuum to give 643 mg of the title
compound. Yield: 93%. 1 H NMR (300 MHz, DMSO-d6) o
1.17-1.50 (m, 16H), 1.60-1.78 (m, 4H), 3.06 (t, 1=7.8 Hz,
4H), 4.27 (s, 6H), 7.95 (dt, 1=6.9, 1.2 Hz, 2H), 8.01 (d, 1=7.8
Hz, 2H), 8.49 (dt, 1=7.8, 1.5 Hz, 2H), 8.95 (d, 1=5.7 Hz, 2H)
ppm; 13 C NMR (75 MHz, DMSO-d6) o 26.5, 28.6, 28.7,
28.9, 29.0, 31.8, 45.2, 124.9, 127.6, 144.9, 146.2, 158.3
ppm.

CH3
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3,3'-(1,12-Dodecanediyl)bispyridine (300 mg, 0.92
mmol) was dissolved in acetone (10 mL). Methyl iodide
(1.42 g, 10 mmol) was added and the mixture was stirred for
12 hrs at room temperature. The precipitate was filtered and
washed with diethyl ether. The obtained pale yellow solid
was dried under vacuum to give 505 mg of the title compound. Yield: 90%. 1 H NMR (300 MHz, CD30D) o 1.101.45 (m, 16H), 1.64-1.82 (m, 4H), 2.89 (t, 1=7 .8 Hz, 4H),
4.52 (s, 6H), 8-92 (dd, 1=8.1, 6.0 Hz, 2H), 8.3.1 ~d, 1=8.1 Hz,
2H), 8.84 (d, 1-6.0 Hz, 2H), 9.00 (s, 2H) ppm, 1 C NMR (75
MHz, CD30D) o 29.0, 29.1, 29.2, 29.3, 30.3, 32.7, 127.7,
142.6, 144.3, 144.6, 144.9 ppm.
Example 5

Example 3
35

Preparation of 4,4'-(1,12-dodecanediyl)bispyridine

Preparation of 3,3'-(1,12-dodecanediyl)bispyridine
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LDA (2M) (20.40 mL, 40.80 mmol) was added dropwise
to a solution of 3-picoline (3.80 g, 40.80 mmol) in THF (60
mL) at -78° C. The mixture was stirred for 30 min and then
1,10-diiododecane (6.43 g, 16.32 mmol) in THF (10 mL)
was added dropwise. The resulting mixture was warmed to
room temperature and stirred for 4 hrs. 50% saturated
NH4 Cl was added to the reaction mixture. The aqueous
phase was extracted with ethylacetate (40 mLx2), and the
combined organic liquors were washed with 50% saturated
brine (40 mLx3) and saturated brine (40 mL ), dried over
anhydrous Na2 S04 , and concentrated under reduced pressure. The crude product was purified by column chromatography (hexanes:ethylacetate 2:1 to 1:1) to afford 3.98 g of
the title compound. Yield: 75%. 1 H NMR (300 MHz,
CDC1 3 ) o 1.17-1.40 (m, 16H), 1.53-1.68 (m, 4H), 2.60 (t,
1=7.5 Hz, 4H), 7.20 (dd, 1=7.8, 1.8 Hz, 2H), 7.48 (dt, 1=7.8,
1.8 Hz, 2H), 8.43 (d, 1=5.1 Hz, 2H), 8.44 (s, 2H) ppm; 13 C
NMR (75 MHz, CDC1 3 ) o29.4, 29.7, 29.8, 29.9, 31.4, 33.3,
123.3, 135.8, 138.4, 147.2, 150.0 ppm.
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LDA (2M) (20 mL, 40.00 mmol) was added dropwise to
a solution of 4-picoline (3.73 g, 40.00 mmol) in THF (60
mL) at -78° C. The mixture was stirred for 30 min and then
1,10-diiododecane (6.31 g, 16.00 mmol) in THF (10 mL)
was added dropwise. The resulting mixture was warmed to
room temperature and stirred for 4 hrs. 50% saturated
NH4 Cl was added to the reaction mixture. The aqueous
phase was extracted with ethylacetate (40 mLx2), and the
combined organic liquors were washed with 50% saturated
brine (40 mLx3) and saturated brine (40 mL ), dried over
anhydrous Na2 S04 , and concentrated under reduced pressure. The crude product was purified by column chromatography (hexanes:ethylacetate 1:1 to 1:2) to afford 4.16 g of
the title compound. Yield: 80%. 1 H NMR (300 MHz,
CDC1 3 ) o 1.18-1.40 (m, 16H), 1.53-1.70 (m, 4H), 2.59 (t,
1=7.5 Hz, 4H), 7.10 (d, 1=6.0 Hz, 4H), 8.48 (d, 1=6.0 Hz,
4H) ppm; 13 C NMR (75 MHz, CDC1 3 ) o 29.4, 29.7, 29.8,
29.9, 30.6, 35.5, 124.0, 149.6, 151.8 ppm.
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Example 6
Preparation of N,N'-dimethyl-4,4'-(1,12-dodecanediyl)bispyridinium diiodide
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4,4'-(1,12-Dodecanediyl)bispyridine (340 mg, 1.05
mmol) was dissolved in acetone (15 mL). Methyl iodide
(1.50 g, 10.6 mmol) was added and the mixture was stirred
for 12 hrs at room temperature. The precipitate was filtered
and washed with diethyl ether. The obtained pale yellow
solid was dried under vacuum to give 599 mg of the title
compound. Yield: 94%. 1 H NMR (300 MHz, DMSO-d6) o
1.17-1.36 (m, 16H), 1.55-1.71 (m, 4H), 2.86 (t, 1=7.8 Hz,
4H), 4.28 (s, 6H), 7.98 (d, 1=6.9 Hz, 4H), 8.84 (d, 1=6.6 Hz,
2H) ppm; 13 C NMR (75 MHz, DMSO-d6) o 28.5, 28.7,
28.9, 29.0, 29.1, 34.5, 47.1, 127.0, 144.5, 161.8 ppm.
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Example 7
Preparation of
3,3'-(1, 12-dodecanediyl)bis-5-methylpyridine
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LDA (2M) (15 mL, 30.00 mmol) was added dropwise to
a solution of3,5-lutidine (3.38 g, 31.50 mmol) in THF (50
mL) at -78° C. The mixture was stirred for 30 min and then
1,10-diiododecane (4.73 g, 12.00 mmol) in THF (10 mL)
was added dropwise. The resulting mixture was warmed to
room temperature and stirred for 4 hrs. 50% saturated
NH4 Cl was added to the reaction mixture. The aqueous
phase was extracted with ethylacetate (40 mLx2), and the
combined organic liquors were washed with 50% saturated
brine (40 mLx3) and saturated brine (40 mL ), dried over
anhydrous Na2 S04 , and concentrated under reduced pressure. The crude product was purified by column chromatography (hexanes:ethylacetate 2:1 to 1:1) to afford 2.82 g of
the title compound. Yield: 67%. 1 H NMR (300 MHz,
CDC1 3 ) o 1.17-1.40 (m, 16H), 1.47-1.68 (m, 4H), 2.30 (s,
6H), 2.56 (t, 1=7.5 Hz, 4H), 7.29 (s, 2H), 8.24 (s, 2H), 8.25
(s, 2H) ppm; 13 C NMR (75 MHz, CDC1 3 ) o18.6, 29.5, 29.7,
29.8, 29.9, 31.5, 33.1, 132.7, 136.5, 137.5, 147.1, 147.7
ppm.
Example 8

45

Preparation of N,N'-dimethyl-3,3'-(1 ,12-dodecanediyl)bis-5-methylpyridinium diiodide
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3,3'-(1,12-Dodecanediyl)bis-5-methylpyridine (300 mg,
0.92 mmol) was dissolved in acetone (10 mL). Methyl
iodide (1.42 g, 10 mmol) was added and the mixture was
stirred for 12 hrs at room temperature. The precipitate was
filtered and washed with diethyl ether. The obtained pale
yellow solid was dried under vacuum to give 477 mg of the
title compound. Yield: 81%. 1 H NMR (300 MHz, CD30D)
01.12-1.47 (m, 16H), 1.65-1.80 (m, 4H), 2.55 (s, 6H), 2.83
(t, 1=7.8 Hz, 4H), 4.37 (s, 6H), 8.30 (s, 2H), 8.65 (s, 2H),
8.69 (s, 2H) ppm; 13 C NMR (75 MHz, CD30D) o 18.6,
30.4, 30.6, 30.8, 30.9, 31.7, 33.6, 140.2, 143.3, 143.9, 144.6,
146.8 ppm.

Example 10
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Preparation of 1-methyl-3-(12-(3-methylpyridin-1ium-1-yl)dodecyl)pyridin-1-ium mono-bromide
mono-iodide
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Preparation of
N-methyl-3-(12-bromododecyl)-pyridinium iodide
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LDA (2M) (10.5 mL, 21.22 mmol) was added dropwise to
a solution of 3-picoline (2.17 g, 23.34 mmol) in THF (60
mL) at -78° C. The mixture was stirred for 30 min and then
1,11-dibromoundecane (10 g, 31.83 mmol) was added in one
portion. The resulting mixture was warmed to oo C. and
stirred for 4 hrs. 50% saturated NH4 Cl was added to the
reaction mixture. The aqueous phase was extracted with
ethylacetate (40 mLx2), and the combined organic liquors
were washed with 50% saturated brine (40 mLx3) and
saturated brine (40 mL), dried over anhydrous Na 2 S04 , and
concentrated under reduced pressure. The crude product was
purified by colunm chromatography (hexanes:ethylacetate
4:1) to afford 4.47 g 3-(12-bromododecyl)-pyridine. Yield:
59%.
The above product (960 mg, 2.95 mmol) was dissolved in
acetone (15 mL). Methyl iodide (2 g, 10.41 mmol) was
added and the mixture was stirred for 12 hrs at room
temperature. The solvent was removed. The residue was
suspended in diethyl ether, filtered, and washed with diethyl
ether. The obtained pale yellow solid was dried under
vacuum to give 1.28 of the title compound. Yield: 93%. 1 H
NMR (300 MHz, CDC1 3 ) 61.13-1.47 (m, 16H), 1.63-1.90
(m, 4H), 2.89 (t, 1=7.8 Hz, 2H), 3.19 (t, 1=6.9 Hz, 2H), 4.70
(s, 3H), 8.04 (dd, 1=7.8, 6.0 Hz, lH), 8.25 (d, 1=7.8 Hz, lH),
9.15 (s, lH), 9.20 (s, 1=6.0 Hz, lH) ppm; 13 C NMR (75
MHz, CDC1 3 ) o 7.8, 28.7, 29.4, 29.5, 29.6, 29.67, 29.70,
29.74, 30.6, 30.7, 33.0, 33.8, 49.6, 127.9, 143.1, 144.2,
144.8 ppm.

35

A mixture of N-methyl-3 -( 12-bromododecy1)-pyridinium
iodide (315 mg, 0.67 mmol), 3-picoline (1 mL) and
butanone (5 mL) was heated at 80° C. for 24 hrs. Solvent
was removed under reduced pressure. The resulted mixture
was washed with diethyl ether and then dissolved in water
(10 mL), the aqueous solution was extracted with chloroform (15 mLx3). Water was removed by lyophilization to
afford 325 mg of the title compound. Yield: 86%. 1 H NMR
(300 MHz, CD30D) o 1.23-1.50 (m, 16H), 1.66-1.81 (m,
2H), 1.94-2.12 (m, 2H), 2.60 (s, 3H), 2.88 (t, 1=7.8 Hz, 2H),
4.43 (s, 3H), 4.63 (t, 1=7.5 Hz, 2H), 7.97-8.05 (m, 2H), 8.45
(t, 1=6.9 Hz, 2H), 8.77 (d, 1=6.0 Hz, lH), 8.87 (d, 1=7.8 Hz,
lH), 8.89 (s, lH), 9.00 (s, lH) ppm; 13 C NMR (75 MHz,
CD30D) o 18.8, 27.3, 30.2, 30.3, 30.55, 30.6, 30.7, 30.8,
31.7, 32.6, 33.7, 63.0, 128.6, 128.7, 141.2, 143.0, 144.1,
145.3, 145.5, 146.2, 146.3, 147.2 ppm.
Example 11
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Preparation of 3,5-dimethyl-1-(12-(1-methylpyridin1-ium-3-yl)dodecyl)pyridin-1-ium mono-bromide
mono-iodide
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A mixture of N-methyl-3 -( 12-bromododecy1)-pyridinium
iodide (285 mg, 0.61 mmol), 3,5-lutidine (1 mL) and
butanone (5 mL) was heated at 80° C. for 24 hrs. Solvent
was removed under reduced pressure. The resulted mixture
was washed with diethyl ether and then dissolved in water
(10 mL), the aqueous solution was extracted with chloro-
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form (15 mLx3). Water was removed by lyophilization to
afford 319 mg of the title compound. Yield: 91%. 1 H NMR
(300 MHz, CD30D) o 1.23-1.48 (m, 16H), 1.68-1.82 (m,
2H), 1.93-2.10 (m, 2H), 2.55 (s, 6H), 2.88 (t, 1=7.8 Hz, 2H),
4.41 (s, 3H), 4.55 (t, 1=7.5 Hz, 2H), 8.00 (dd, 1=7.8, 6.0 Hz,
lH), 8.27 (s, lH), 8.45 (d, 1=7.8 Hz, lH), 8.75 (s, 2H), 8.76
(d, 1=6.0 Hz, lH), 8.88 (s, lH) ppm; 13 C NMR (75 MHz,
CD30D) o 18.5, 27.4, 30.28, 30.3, 30.6, 30.64, 30.7, 30.8,
31.7, 32.7, 33.7, 62.8, 128.7, 140.4, 142.7, 144.1, 145.4,
146.3, 147.8 ppm.
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Example 12
Preparation of (S)-1-methyl-3-(12-(3-(1-methylpyrrolidin-2-yl)pyridin-1-ium-1-yl)dodecyl)pyridin-1ium mono-bromide mono-iodide
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A mixture of N-methyl-3-(12-bromododecyl)-pyridinium
iodide (250 mg, 0.53 mmol), S-nicotine (1 mL) and
butanone (5 mL) was heated at 80° C. for 24 hrs. Solvent
was removed under reduced pressure. The resulted mixture
was washed with diethyl ether and then dissolved in water
(10 mL), the aqueous solution was extracted with chloroform (15 mLx3). Water was removed by lyophilization to
afford 270 mg of the title compound. Yield: 81%. 1 H NMR
(300 MHz, CD30D) o 1.15-1.40 (m, 16H), 1.62-1.77 (m,
2H), 1.80-2.10 (m, 5H), 2.23 (s, 3H), 2.35-2.56 (m, 2H),
2.87 (t, 1=7.8 Hz, 2H), 3.32 (m, lH), 3.58 (t, 1=8.4 Hz, lH),
4.37 (s, 3H), 4.64 (t, 1=7.5 Hz, 2H), 7.95 (dd, 1=8.1, 6.3 Hz,
lH), 8.09 (dd, 1=8.1, 6.3 Hz, lH), 8.40 (d, 1=7.8 Hz, lH),
8.53 (d, 1=8.1 Hz, lH), 8.61 (d, 1=6.0 Hz, lH), 8.68 (s, lH),
8.82 (d, 1=6.9 Hz, lH), 8.83 (s, lH) ppm; 13 C NMR (75
MHz, CD30D) o 22.4, 25.4, 28.3, 28.7, 28.8, 28.9, 29.0,
29.9, 30.8, 32.2, 34.0, 39.5, 48.2, 56.7, 62.3, 67.6, 127.5,
128.5, 142.4, 143.4, 143.5, 143.7, 144.2, 144.5, 144.6, 145.2
ppm.

A mixture of N-methyl-3 -( 12-bromododecy1)-pyridinium
iodide (250 mg, 0.53 mmol), pyridine (1 mL) and butanone
(5 mL) was heated at 80° C. for 24 hrs. Solvent was removed
under reduced pressure. The resulted mixture was washed
with diethyl ether and then dissolved in water (10 mL), the
aqueous solution was extracted with chloroform (15 mLx3).
Water was removed by lyophilization to afford 278 mg of the
title compound. Yield: 95%. 1 H NMR (300 MHz, CD30D)
o1.20-1.50 (m, 16H), 1.65-1.82 (m, 2H), 1.95-2.12 (m, 2H),
2.88 (t, 1=7.8 Hz, 2H), 4.42 (s, 3H), 4.68 (t, 1=7.5 Hz, 2H),
8.00 (t, 1=6.9 Hz, lH), 8.14 (t, 1=6.9 Hz, 2H), 8.45 (d, 1=7.8
Hz, lH), 8.62 (t, 1=7.8 Hz, lH), 8.76 (d, 1=6.0 Hz, lH), 8.88
(s, lH), 9.07 (d, 1=5.4 Hz, 2H) ppm; 13 C NMR (75 MHz,
CD30D) o 27.3, 30.2, 30.3, 30.6, 30.63, 30.7, 30.8, 31.7,
32.7, 33.7, 63.2, 128.7, 129.5, 144.1, 145.3, 145.9, 146.2,
146.3, 146.8 ppm.
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Example 13
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Preparation of 1-methyl-3-(12-(pyridin-1-ium-1-yl)
dodecyl)pyridin-1-ium mono-bromide mono-iodide

Inhibition of [3 H]NIC and [3 H]Methyllycaconitine
Binding Assays
Whole brain, excluding cortex and cerebellum, was
homogenized in 20 vol of ice-cold buffer, containing (in
mM): 2 HEPES, 11.8 NaCl, 0.48 KCl, 0.25 CaC1 2 and 0.12
MgS04 , pH 7.5. Homogenate was centrifuged (25,000 g, 15
min, 4° C.). Pellets were resuspended in 20 vol buffer and
incubated at 37° C., for 10 min, cooled to 4° C. and
centrifuged (25,000 g, 15 min, 4° C.). Pellets were resuspended and centrifuged using the same conditions. Final
pellets were stored in assay buffer, containing (in mM): 20
HEPES, 118 NaCl, 4.8 KCl, 2.5 CaC1 2 , and 1.2 MgS04 , pH
7.5 at -70° C. Upon use, final pellets were resuspended in
-20 vol assay buffer. Samples (250 fll) contained 100-140 flg
of membrane protein, 3 nM [3 H]nicotine or 3 nM [3 H]
methyllycaconitine, and analog (1 00 nM) in assay buffer
containing 50 mM Tris. Control was in the absence of
analog. In [3 H]nicotine and [3 H]methyllycaconitine binding
assays, nonspecific binding was determined in the presence
of 10 f.LM cytisine and 10 f.LM nicotine, respectively. Incubations proceeded for 60 min at room temperature using
96-well plates and were terminated by harvesting on Unifilter-96 GF/B filter plates presoaked in 0.5% polyethylenimine, using a Packard FilterMate harvester. After washing
5 times with 350 fll ice-cold assay buffer, filter plates were
dried (60 min, 4° C.), bottom-sealed, and filled with Packard's MicroScint 20 cocktail (40 fll/well). After 60 min, filter
plates were top-sealed, and radioactivity determined using a
Packard TopCount. Protein concentrations were determined
using the Bradford dye-binding procedure bovine serum
albumin as the standard. The results are summarized in Table
1.
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Example 15
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Inhibition of Nicotine-Evoked [3 H]Neurotransmitter
Release Assay
65

The [3 H]dopamine overflow assay using superfused rat
striatal slices preloaded with [3 H]dopamine was used to
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determine the ability of a probe concentration (100 nM) of
each his-quaternary ammonium analog to inhibited nicotineevoked [3 H]dopamine overflow. Briefly, coronal slices of rat
striata (500 fllll, 6-8 mg) were obtained using a Mcilwain
tissue chopper. Slices were incubated for 30 min in Krebs'
buffer (in mM: 118 NaCl, 4.7 KCl, 1.2 MgC1 2 , 1.0
NaH 2 P04 , 1.3 CaC1 2 , 11.1 a-D-glucose, 25 NaHC0 3 , 0.11
L-ascorbic acid and 0.004 ethylenediaminetetraacetic acid
(EDTA), pH 7.4, saturated with 95% 0 2 /5% C0 2 ) at 34° C.
in a metabolic shaker. Slices were then incubated for an
3
additional 30 min in fresh buffer containing 0.1 f.LM [ H]
dopamine. After rinsing, each slice was transferred to each
one of 20 superfusion chambers, maintained at 34 o C. and
superfused (0.6 ml/min) with oxygenated Krebs' buffer in a
Brandel Suprafusion 2500 (Biomedical Research and Development Laboratories, Inc., Gaithersburg, Md.). The buffer
contained both nomifensine (1 0 f.LM), a dopamine uptake
blocker, and pargyline (10 f.LM), a monoamine oxidase
inhibitor, ensuring that [3 H]overflow primarily represented
3
[ H]dopamine,
rather than [3 H]metabolites. Following
superfusion for 60 min, two 4-min samples (2.4 ml/sample)
were collected to determine basal [3 H]outflow. After collection of the second basal sample, slices from an individual rat
were superfused for 40 min in the absence (0 nM; control)
or presence of each his-quaternary ammonium analog (1 00
nM) to determine the intrinsic activity of the analog, i.e.,
ability of the analog to evoke [3 H]overflow. Following 40
min of superfusion in the absence or presence of analog,
nicotine (10 f.LM) was added to the superfusion buffer and
samples were collected for an additional 40 min to deter-

CaC1 2 , 11.1 mM glucose, 25 mM NaHC0 3 , 0.11 mM
L-ascorbic acid, and 0.004 mM disodium EDTA; pH 7.4,
and saturated with 95% 0i5% C0 2 ) in a metabolic shaker
at 34 o C. Slices were rinsed with 15 mL of fresh buffer and
incubated for an additional 30 minutes in fresh buffer
containing 0.1 f.LM [3 H]dopamine (DA; 6 slices/3 mL).
Subsequently, slices were rinsed with 15 mL of fresh buffer
and transferred to a glass superfusion chamber. Slices were
superfused (1.0 mL/min) for 60 minutes with Krebs buffer
containing nomifensine (10 f.LM) and pargyline (10 f.LM) and
maintained at 34° C., pH 7.4, with continual aeration (95%
0 2 /5% C0 2 ). Three 5-minute samples (5 mL each) were
collected to determine basal outflow of [3 H]DA. The hisquaternary analogs were added to the superfusion buffer
after the collection of the third sample and remained in the
buffer until 12 consecutive five minute samples were collected. Subsequently, S-(-)-nicotine (1 0 f.LM) was added to
the buffer and an additional 12 consecutive five minute
samples were collected. At the end of the experiment, each
slice was solubilized and the [3 H] content of the tissue
determined. Radioactivity in the superfusate and tissue
samples was determined by liquid scintillation spectroscopy.
Fractional release for tritium collected in each sample was
divided by the total tritium present in the tissue at the time
of sample collection and was expressed as a percentage of
total tritium. Basal [3 H]outflow was calculated from the
average of the tritium collected in the two five minute
samples just before addition of the quaternary analog. The
sum of the increase in collected tritium resulting from either
exposure to the test compound or exposure to S(-)nicotine
in the absence and presence of the test compound equaled
total [3 H]overflow. [3 H]Overflow was calculated by subtracting the [3 H]outflow during an equivalent period of
prestimulation from the values in samples collected during
and after drug exposure. Inasmuch as the radiolabelled
compounds were not separated and identified, the tritium
collected in superfusate is referred to as either [3 H]outflow
or [3 H]overflow, rather than as [3 H]dopamine. [3 H]Overflow
primarily represents [3 H]dopamine in the presence of
nomifensine and pargyline in the superfusion buffer.
All of the his-quaternary analogs were evaluated for their
ability to evoke [3 H]dopamine release from rat striatal slices
using the probe 100 nM concentration (Table 1). None of the
compounds examined had any significant [3 H]dopamine
releasing properties in this assay in the concentration range
tested. One analog GZ527B was evaluated for full concentration dependent inhibition of the effect of nicotine to evoke
3
[ H]dopamine release (FIG. 1). In both studies, the antagonist activity was evaluated by comparing the NIC-evoked
3
[ H]overflow in the absence and presence of the analogs.
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experiment was superfused for 40 min in the absence of
analog, followed by superfusion with 10 f.LM nicotine to
determine nicotine-evoked [3 H]dopamine overflow in the
absence of analog (nicotine control). After collection of the
superfusate samples, the slices were retrieved from the
chambers and solubilized using 1 ml of TS-2 tissue solubilizer. Scintillation cocktail (4 ml) was added to the superfusate samples. The pH and volume of the solubilized tissue
samples were adjusted to that of the superfusate samples.
Radioactivity in the superfusate and tissue samples was
determined by liquid scintillation spectroscopy (Packard
model B 1600 TR Scintillation Counter, Downer's Grove,
Ill.).
For individual analogs, a complete concentration response
was determined using the following methodology. Rat striatal slices (500 f.tm thickness, 6-8 mg wet weight) were
incubated for 30 minutes in Krebs buffer (118 mM NaCl, 4.7
mM KCl, 1.2 mM MgC1 2 , 1.0 mM NaH 2 P04 , 1.3 mM
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TABLE 1
his-Quaternary Ammonium Salts Inhibition of [3 H]NIC and ['H]MLA Binding to
Rat Striatal Nicotinic Receptors and Nicotine-evoked [3 H]Dopamine Release from
Superfused Rat Striatal Slices

COMPOUND

Inhibition
Nicotineevoked
Inhibition of Inhibition of
['H]DA
3
3
[ H]Nicotine
[ H]MLA
release
Binding
binding
(%
inhibition at
Ki(f!M;
Ki(f!M;
M ± SEM)
M ± SEM)
100 nM)
8.20 ± 1.78

>100

32%
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TABLE !-continued
his-Quaternary Ammonium Salts Inhibition of [3 H]NIC and [3 H]MLA Binding to
Rat Striatal Nicotinic Receptors and Nicotine-evoked [3 H]Dopamine Release from
Superfused Rat Striatal Slices
Inhibition
Nicotineevoked
3
Inhibition of Inhibition of
[ H]DA
3
3
[ H]Nicotine
[ H]MLA
release
binding
Binding
(%
Ki (f]M;
inhibition at
Ki(f!M;
M ± SEM)
M ± SEM)
100 nM)

COMPOUND
GZ-527A

H;C/~'-m,

7.88 ± 1.68

>100

67%

8.17±0.17

>100

49%

>100

>100

30%

>100

>100

43%

>100

>100

25%

6.62 ± 1.14

>100

43%

23.4 ± 3.94

>100

9%

2I
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CH3
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I
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aData are % inhibition at 100 nM concentration of the
his-quaternary analogs for at least 1-3 independent experiments. Specific binding in the [3H]NIC binding assay is
calculated as the difference between the total binding of 3
nM [3H]NIC and nonspecific binding in the presence of 10
f.LM cytisine. Specific binding for the [3H]MLA binding
assay is calculated as the difference between the total
binding of 3 nM [3H]MLA to the receptors alone and its
nonspecific binding in the presence of 10 f.LM nicotine.
Analog-induced inhibition of nicotine-evoked [3H]DA
release is calculated as a percent of that in the absence of the
his-quaternary anmwnium analog.
It will be appreciated that, although specific embodiments
of the invention have been described herein for purposes of
illustration, various modifications may be made without
departing from the spirit and scope of the invention. All such
modifications and variations are intended to be included
herein within the scope of this disclosure and the present
invention and protected by the following claims.
We claim:
1. A his-quaternary monium compound of Formula (I)

Y 5 are each independently selected from hydrogen,
alkyl, cycloalkyl, alkenyl, alkynyl, aryl, alkylaryl, arylalkyl, arylalkenyl, arylalkynyl, acyl, alkylsulfonyl,
arylsulfonyl, or heterocyclic, where if Y 4 or Y 5 comprises alkenyl or alkynyl, the site ofunsaturation is not
conjugated with the nitrogen; SY 6 , where Y 6 is selected
from hydrogen, alkyl, cycloalkyl, alkenyl, alkynyl,
aryl, alkylaryl, arylalkyl, arylalkenyl, arylalkynyl, or
heterocyclic, and where if Y 6 comprises alkenyl or
alkynyl, the site ofunsaturation is not conjugated with
the sulfur; and any of R 5 , R 7 , R 9 , R u, or R 13 attached
to the quaternized nitrogen is independently a straight
or branched alkyl group of four carbons or fewer.
2. The compound of claim 1, wherein:
R is -(CH 2 ) 12- ;
R 1 and R 2 are pyridinium rings;
A 3 is nitrogen;
R 7 is methyl;
Ru is hydrogen or methyl; and
X 1 and X 2 are bromide or iodide.
3. The compound of claim 1, wherein:
R is -(CH 2 ) 12- ;
R 1 and R 2 are pyridinium rings;
A 4 is nitrogen;
R 9 is methyl; and
X 1 and X 2 are bromide or iodide.
4. The compound of claim 1, wherein:
R is -(CH 2 ) 12- ;
R 1 and R 2 are pyridinium rings;
wherein for R 1, A 3 is nitrogen, R 7 is methyl, Ru is
hydrogen or methyl, and X 1 is bromide or iodide; and
wherein for R 2, A 1 is nitrogen, R 7 and Ru is hydrogen,
methyl or 1-methyl-2-pyrrolidinyl, and X 2 is bromide
or iodide.
5. The compound of claim 1 selected from the group
consisting of:
N,N'-dimethyl-3,3'-(1,12-dodecanediyl)bispyridinium
diiodide;
N,N'-dimethyl-4,4'-(1,12-dodecanediyl)bispyridinium
diiodide;
N,N'-dimethyl-3,3'-(1,12-dodecanediyl)bis-5-methylpyridinium diiodide;
1-methyl-3-(12-(3-methylpyridin-1-ium-1-yl)dodecyl)
pyridin -1-ium mono-bromide mono-iodide;
3,5-dimethyl-1-(12-(1-methylpyridin-1-ium-3-yl)dodecyl)pyridin-1-ium mono-bromide mono-iodide; and
1-methyl-3-(12-(pyridin-1-ium-1-yl)dodecyl)pyridin-1ium mono-bromide mono-iodide.
6. A his-quaternary ammonium compound of Formula (I)

X 2 8EBR2 -R-R 1EB8X 1
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wherein X 18 and X 28 are each independently an organic
or inorganic anion;
wherein R is selected from the group consisting of
-(CH2)12-;
wherein R 1 and R 2 are each six membered rings as shown
in formula (IIA), wherein each ring of R 1 and R 2 has
one quaternized nitrogen atom, and the ring atoms from
R 1 and R 2 which are attached to R cannot both be
nitrogen atoms:
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wherein one of A 1, A 3, and A 4 , is nitrogen and the
remaining A\ A 2, A 3, A 4 , A 5 , and A 6 are carbon;
wherein R 5 , R 7 , R 9 , Ru, and R 13 are each independently
selected from hydrogen, alkyl, substituted alkyl,
cycloalkyl, substituted cycloalkyl, alkenyl, substituted
alkenyl, alkynyl, substituted alkynyl, aryl, substituted
aryl, alkylaryl, substituted alkylaryl, arylalkyl, substituted arylalkyl, arylalkenyl, substituted arylalkenyl,
arylalkynyl, substituted arylalkynyl, halo, cyano, nitro,
SOY\ S0 2Y\ S0 20Y 1 or S0 2NHY 1, where Y 1 is
selected from hydrogen, lower alkyl, alkenyl, alkynyl
or aryl, and where Y 1 is not hydrogen in SOY 1 and if
Y 1 is alkenyl or alkynyl, the site ofunsaturation is not
conjugated with a heteroatom; COY2, where Y 2 is
selected from hydrogen, alkyl, cycloalkyl, alkoxy, alkenyl, alkynyl, aryl, alkylaryl, arylalkyl, arylalkenyl,
arylalkynyl, or heterocyclic, and where ifY2 comprises
alkenyl or alkynyl, the site of unsaturation is not
conjugated with the carbonyl group; OY3, where Y 3 is
selected from hydrogen, alkyl, cycloalkyl, alkenyl,
alkynyl, aryl, alkylaryl, arylalkyl, arylalkenyl, arylalkynyl, acyl, alkylsulfonyl, or heterocyclic, where ifY3
comprises alkenyl or alkynyl, the site ofunsaturation is
not conjugated with the oxygen; NY4 Y 5 , where Y 4 and
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wherein X 18 and X 28 are each independently an organic
or inorganic anion;
wherein R is selected from the group consisting of
-(CH2)12-;
wherein R 1 and R 2 are each six membered rings as shown
in formula (IIA), wherein each ring of R 1 and R 2 has
one quaternized nitrogen atom, and the ring atoms from
R 1 and R 2 which are attached to R cannot both be
nitrogen atoms:
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N,N'-dimethyl-4,4'-(1,12-dodecanediyl)bispyridinium
diiodide;
N,N'-dimethyl-3,3'-(1,12-dodecanediyl)bis-5-methylpyridinium diiodide;
1-methyl-3-(12-(3-methylpyridin-1-ium-1-yl)dodecyl)
pyridin-1-ium mono-bromide mono-iodide·

(IIA)

3,5-dimethyl-1-(12-(1-methylpyridin-1-ium-3~yl)dode
wherein one of A 1 , A 3 , and A 4 is nitrogen and the
remaining A\ A\ A 3 , A 4 , A 5 , and A 6 are carbon·
· Rs , R7 , R9 , Ru , and R 13 are each independently
'
w herem
sel~c~ed from hydrogen, methyl, and 1-methyl-2-pyrrohdmyl; and any ofR5 , R7, or R9, when attached to the
quaternized nitrogen, is independently a straight or
branched lower alkyl group.
. 7. .CS)-1-methyl-3-(12-(3-(1-methylpyrrolidin-2-yl)pyridm-1-mm-1-yl)dodecyl)pyridin-1-ium
mono-bromide
mono-iodide.
8. A c?mposition comprising a pharmaceutically acceptable earner and a compound of claim 1.
9. A c?mposition comprising a pharmaceutically acceptable earner and a compound of claim 2.
10. A ~omposition comprising a pharmaceutically acceptable earner and a compound of claim 3.
11. A ~omposition comprising a pharmaceutically acceptable earner and a compound of claim 4.
12. A ~omposition comprising a pharmaceutically acceptable earner and a compound of claim 5.
13. A ~omposition comprising a pharmaceutically acceptable earner and a compound of claim 7.
1~ . .A ~ethod for treating substance abuse comprising
admm1stenng to a mammalian subject in need thereof a
t~erapeutically effective amount of a his-quaternary ammomum compound selected from the group consisting of:
N,N'-dimethyl-2,2'-(1,12-dodecanediyl)bispyridinium
diiodide;
N,N'-dimethyl-3,3'-(1,12-dodecanediyl)bispyridinium
diiodide;
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cyl)pyridin-1-ium mono-bromide mono-iodide·
(S )-1.-methyl-3 -( 12-(3 -( 1-methylpyrrolidin-2-y l)p~ridin1-mm-1-yl)dodecyl)pyridin-1-ium
mono-bromide
mono-iodide; and
1-methyl-3-(12-(pyridin-1-ium-1-yl)dodecyl)pyridin-1ium mono-bromide mono-iodide
wherei1_1 t~e sub~tan~e abuse is sel~cted from the group
cons1stmg of mcotme abuse, cocaine abuse, and alcohol
abuse.
15. The method for treating substance abuse according to
~!aim 14, wherein the his-quaternary ammonium compound
1s selected from the group consisting of:
N,N'-dimethyl-2,2'-(1,12-dodecanediyl)bispyridinium
diiodide;
N,N'-dimethyl-3,3'-(1,12-dodecanediyl)bispyridinium
diiodide;
N,N'-dimethyl-4,4'-(1,12-dodecanediyl)bispyridinium
diiodide;
N,N'-dimethyl-3,3'-(1,12-dodecanediyl)bis-5-methylpyridinium diiodide;
1-methyl-3-(12-(3-methylpyridin-1-ium-1-yl)dodecyl)
pyridin-1-ium mono-bromide mono-iodide·

3,5-dimethyl-1-(12-(1-methylpyridin-1-ium-3~yl)dode
cyl)pyridin-1-ium mono-bromide mono-iodide· and

(S)-1-methyl-3-(12-(3-(1-methylpyrrolidin-2-yl)p~ridin35

1-ium-1-yl)dodecyl)pyridin-1-ium
mono-bromide
mono-iodide.
16. The method for treating substance abuse according to
claim 14, wherein the his-quaternary ammonium compound
is
N,N'-dimethyl-4,4'-(1,12-dodecanediyl)bispyridinium
diiodide.
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